Tvardi Therapeutics, Inc.

TVRD

Healthcare|Biotechnology|US

$0.96

+0.09 (+10.79%)

DCF Value

$2.25

Tangible Book / Share

$0.86

Cash / Share

$1.68

About

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Stock Price

-75.7%(1Y)

-11.3%

-48.8%

-77.1%

YTD

-77.7%

-77.1%

-80.5%

Pipeline Summary

7 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Withdrawn: 2Completed: 2Terminated: 1Recruiting: 2

Active Trials (2)

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

NCT05440708Hepatocellular Carcinoma

Phase 1Phase 2Recruiting

Enrollment: 193 participants

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT06141031Pancreatic Cancer

Phase 1Recruiting

Enrollment: 24 participants

Key Facts

Market Cap$12.8M

Employees12

CEOImran Alibhai

IPO DateJan 31, 2014

Beta0.36

52-Week Range$0.7729 – $5.69

Avg Volume1,696,393

ExchangeNASDAQ

Websitetvarditherapeutics.com

Ownership

Float72.2%

Shares Outstanding13.3M